Biotech · Private company
Medicago
Track this companyFree. Adds Medicago to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- Fluarix Quadrivalent® Comparator VaccinePhase 3 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- Intramuscular injectionPhase 3 · SARS-CoV-2 InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Intramuscular vaccinePhase 3 · SARS-CoV-2 InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Quadrivalent VLP VaccinePhase 3 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- 15 µg/strain of Quadrivalent VLP VaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- 15 µg/strain of the licensed quadrivalent vaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- 30 µg/strain of Quadrivalent VLP VaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- 60 µg/strain of Quadrivalent VLP VaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- FluLaval® Tetra (15 µg/strain)Phase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- Fluzone® High-Dose (60 µg/strain)Phase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- High dose of quadrivalent VLP vaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- Instramuscular vaccinePhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Low dose of quadrivalent VLP vaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- Medium dose of quadrivalent VLP vaccinePhase 2 · Virus DiseasesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in AdultsPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 19, 2020ClinicalTrials.gov NCT04636697 · fetched Nov 12, 2026
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and OlderPHASE1_PHASE2 · COMPLETED · started Nov 2, 2020ClinicalTrials.gov NCT04622592 · fetched Nov 12, 2026
- Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the ElderlyPHASE3 · COMPLETED · started Sep 18, 2018ClinicalTrials.gov NCT03739112 · fetched Nov 12, 2026
- Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsPHASE3 · COMPLETED · started Aug 31, 2017ClinicalTrials.gov NCT03301051 · fetched Nov 12, 2026
- Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly AdultsPHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02831751 · fetched Nov 12, 2026
- Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy AdultsPHASE2 · COMPLETED · started Mar 2, 2016ClinicalTrials.gov NCT02768805 · fetched Nov 12, 2026
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in AdultsPHASE2 · COMPLETED · started Jul 28, 2014ClinicalTrials.gov NCT02233816 · fetched Nov 12, 2026
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsPHASE1_PHASE2 · COMPLETED · started Oct 8, 2013ClinicalTrials.gov NCT01991587 · fetched Nov 12, 2026